- Home
- PSNL vs CNTB Comparison
PSNL vs CNTB Comparison
Compare PSNL & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- CNTB
- Stock Information
- Founded
- PSNL 2011
- CNTB 2012
- Country
- PSNL United States
- CNTB United States
- Employees
- PSNL N/A
- CNTB N/A
- Industry
- PSNL Medical Specialities
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- CNTB Health Care
- Exchange
- PSNL Nasdaq
- CNTB Nasdaq
- Market Cap
- PSNL 321.1M
- CNTB 68.5M
- IPO Year
- PSNL 2019
- CNTB 2021
- Fundamental
- Price
- PSNL $5.19
- CNTB $1.17
- Analyst Decision
- PSNL Strong Buy
- CNTB Strong Buy
- Analyst Count
- PSNL 4
- CNTB 1
- Target Price
- PSNL $6.81
- CNTB $8.00
- AVG Volume (30 Days)
- PSNL 439.4K
- CNTB 24.6K
- Earning Date
- PSNL 11-06-2024
- CNTB 09-05-2024
- Dividend Yield
- PSNL N/A
- CNTB N/A
- EPS Growth
- PSNL N/A
- CNTB N/A
- EPS
- PSNL N/A
- CNTB N/A
- Revenue
- PSNL $80,027,000.00
- CNTB $24,116,000.00
- Revenue This Year
- PSNL $10.85
- CNTB N/A
- Revenue Next Year
- PSNL $8.77
- CNTB $63.90
- P/E Ratio
- PSNL N/A
- CNTB N/A
- Revenue Growth
- PSNL 19.20
- CNTB N/A
- 52 Week Low
- PSNL $0.89
- CNTB $0.68
- 52 Week High
- PSNL $7.20
- CNTB $2.84
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- CNTB 44.02
- Support Level
- PSNL $4.54
- CNTB $1.18
- Resistance Level
- PSNL $5.35
- CNTB $1.26
- Average True Range (ATR)
- PSNL 0.30
- CNTB 0.07
- MACD
- PSNL 0.05
- CNTB -0.01
- Stochastic Oscillator
- PSNL 84.71
- CNTB 13.59
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.